INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024

Boca Raton, Florida, Feb. 06, 2024 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) with XPro^TM (XPro1595; pegipanermin), a dominant-negative inhibitor of soluble TNF, announces its management will be participating in Baird’s Biotech Discovery Series webcast on Tuesday, February 13, 2024 at 10:30AM EST.  The webcast will feature RJ Tesi, MD, CEO, CJ Barnum, PhD, head of Neuroscience, and Malu Tansey, PhD, Professor of Neuroscience and Neurology, Norman and Susan Fixel Chair in Parkinson’s Disease, Director, Parkinson’s Foundation Research Center of Excellence, University of Florida.

The speakers will cover two key topics – first, they will provide an update on the unique features of the Company’s  ongoing blinded, randomized, placebo-controlled Phase II trial for Early Alzheimer's disease (MCI/Mild AD).  Additionally, the group will highlight the predecessor Phase I trial data that demonstrated that neutralizing soluble TNF with XPro and preserving transmembrane TNF function decreased neuroinflammation (decreased inflammatory cytokines in the CFS and decrease White Matter Free Water in white matter tracts), decreased neurodegeneration (46% decrease in pTau217; 84% decrease in NFL), improved synaptic function and promoted remyelination of axons.

Those who wish to view the discussion can register for the webcast by clicking here.

Link: https://goto.webcasts.com/starthere.jsp?ei=1655791&tp_key=48e19840e0&sti=gib

Baird’s Biotech Discovery Series, which launched in early 2022, is an opportunity for investors to hear directly from interesting and innovative public and private biotech companies in a fireside chat format. Each episode is centered around a key event for the focus company, which can include new clinical data, a material regulatory event, key management additions, a significant new investment, a key acquisition, new entry into the public markets, etc. We invite key members of management and frequently ask related third parties to join the discussion to learn why they are excited about the science and opportunity for these emerging biotech leaders.